论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Wolf DC, Jaganathan S, Burudpakdee C, Seetasith A, Low R, Lee E, Gucky J, Yassine M, Schwartz DA
Received 10 August 2017
Accepted for publication 11 December 2017
Published 21 May 2018 Volume 2018:12 Pages 869—878
DOI https://doi.org/10.2147/PPA.S148777
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Akshita Wason
Peer reviewer comments 2
Editor who approved publication: Dr Johnny Chen
Background: Patient support programs have a positive effect on adherence to
therapy. Certolizumab pegol (CZP) is a tumor necrosis factor antagonist for the
treatment of Crohn’s disease.
Objectives: To assess, using real-world claims data, whether
home health nurse assistance had an effect on patients’ adherence to CZP and to
measure its impact on health care use and costs.
Methods: A retrospective analysis of medical and pharmacy
claims data from the IQVIA Real-World Data Adjudicated Claims Database was
conducted using data from January 1, 2007 through September 30, 2015. CZP
patients with Crohn’s disease were eligible to receive self-administration
instructions from a nurse or nurse-administered CZP injections, or both. These
services were provided by CIMplicity®, a home health
nurse program sponsored by UCB Pharma. Cohorts were based on patients with and
without nurse assistance and were matched based on gender and categorical age.
Adherence to CZP was determined using the medication possession ratio (MPR) and
proportion of days covered (PDC). A Kaplan–Meier analysis was performed to
compare time to discontinuation of CZP between the two cohorts. Multivariate
regression analyses were performed, adjusting for additional covariates to
compare the effect of CZP with and without nurse assistance on hospitalization
and total health care costs.
Results: Patients with at least 12 months of continuous
enrollment post-index date were evaluated for adherence to CZP (n=276 in each
cohort). The mean and median PDC and MPR values were higher with nurse
assistance than without. Time to discontinuation was significantly longer in
patients who received CZP with nurse assistance than without (P =0.0004). Results from the
multivariate analyses showed a significant reduction in all-cause
hospitalization (-55.8%; P =0.0026) and total
health care costs (-14.3%; P =0.0045) with
nurse assistance.
Conclusion: This analysis suggests that home health nurse
assistance increases adherence to CZP and reduces health care costs in patients
with Crohn’s disease.
Keywords: certolizumab
pegol, adherence, cost, nurse assistance, patient support program, Crohn’s disease,
claims data
摘要视频链接:Home health nurse assistance
in patients receiving certolizumab pegol